Array Biopharma: When Clinical Trial Results Talk

Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating the firm’s MEK inhibitor drug binimetinib, and its BRAF inhibitor drug encorafenibin in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The part 2 of the Phase 3, which intended to compare progression free survival (PFS) in patients treated with binimetinib plus encorafenib (COMBO300) to patients treated with encorafenib as a single agent.

The results confirmed the following:

Regarding progression free survival (PFS): The . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.